Verstovsek Outlines Features of and Therapies for Myeloproliferative Neoplasms
In an article published by Targeted Oncology, Dr. Srdan Verstovsek, MD, Ph.D., discussed with a group of physicians the considerations he makes with the diagnosis and management of patients with myeloproliferative neoplasms (MPNs). Read Dr. Verstovsek's answers to questions such as, what are important diagnostic parameters of myelofibrosis, how do you treat patients with MDS/MPN, what is the best therapy, what risk assessment models are available for prognosis, and how does this affect the choice of therapy.
From the article, we can conclude that serial genetic sequencing is important for prognostics as well as for understanding which if any drug trial a patient could be a good fit for. And while this is readily known by cancer centers who see more MPN patients and are up to date on the publications, it is not routine practice, therefore, patients are not receiving the proper testing and often times insurers are not covering it.